Health
Medical
Biotechnology

bluebird bio

$133.66
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$2.09 (-1.54%) Today
$0.00 (0.00%) As of 4:28 PM EDT after-hours

Why Robinhood?

You can buy or sell bluebird bio and other stocks, options, ETFs, and crypto commission-free!

About BLUE

bluebird bio, Inc. Common Stock, also called bluebird bio, is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Read More Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Employees
764
Headquarters
Cambridge, Massachusetts
Founded
1992
Market Cap
7.48B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
513.63K
High Today
$136.85
Low Today
$133.20
Open Price
$136.50
Volume
383.24K
52 Week High
$181.77
52 Week Low
$87.49

Collections

Health
Medical
Biotechnology
Cancer Prevention
Gene Therapies
Technology
Therapy
2013 IPO

BLUE News

Seeking AlphaJun 20

bluebird bio: Returning To A Previous Winner

450
Barron'sJun 18

Bluebird Bio Stock Rises on Analyst’s Buy Call

357
Seeking AlphaJun 18

Maxim turns bullish on Bluebird

119

BLUE Earnings

-$2.99
-$2.56
-$2.12
-$1.69
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours

More BLUE News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.